GSK Partners With Zhifei to Boost Shingles Vaccine Availability in China
By Michael Susin
GSK said it has an exclusive agreement with Chongqing Zhifei Biological Products to co-promote its shingles vaccine Shingrix in China.
The British pharmaceutical giant on Monday said that Zhifei will have exclusive rights to import and distribute Shingrix in the country for an initial three-year period starting from Jan. 1.
The deal will significantly extend the availability of the vaccine to healthcare professionals and over 30,000 points of vaccination, it said.
Zhifei is the largest Chinese vaccine company by revenue, GSK said.
The partnership will also support potential future co-development and commercialization of GSK's respiratory syncytial virus vaccine Arexvy in the country.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
October 09, 2023 02:30 ET (06:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back